Pharma pricing and drug development legal battles

Pharmaceutical companies face legal scrutiny over pricing practices and drug development decisions, with courts issuing mixed rulings on state attorneys general and patient class actions. Recent decisions involve Eli Lilly's insulin pricing investigation in Michigan and Gilead Sciences' HIV drug development timeline in California.